| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/18/2009 | EP2024361A1 3-tetrazolyl indazoles, 3-tetrazolyl pyrazolopyridines, and use thereof |
| 02/18/2009 | EP2024360A2 Substituted pyrazolopyrimidines |
| 02/18/2009 | EP2024359A1 Compounds that are agonists of muscarinic receptors and that may be effective in treating pain, alzheimer's decease and/or schizophrenia |
| 02/18/2009 | EP2024358A1 Substituted spirocyclic cgrp receptor antagonists |
| 02/18/2009 | EP2024357A2 New heterocyclic compounds for the inhibition of integrins and use thereof |
| 02/18/2009 | EP2024356A1 Bicyclic derivatives as cetp inhibitors |
| 02/18/2009 | EP2024355A2 Alkene piperidine derivatives as antiviral agents |
| 02/18/2009 | EP2024354A1 1- [ (4- [benzoyl (methyl) amino]-3- (phenyl) butyl]azetidine derivatives for the treatment of gastrointestinal disorders 1 |
| 02/18/2009 | EP2024353A2 Pyrazole compounds |
| 02/18/2009 | EP2024352A1 Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
| 02/18/2009 | EP2024349A2 Novel compounds as cannabinoid receptor ligands and uses thereof |
| 02/18/2009 | EP2024348A2 Benzoxazole and benzothiazole derivatives as 5-hydroxytrytamine-6 ligands |
| 02/18/2009 | EP2024347A1 Phenylamino-benzoxazole substituted carboxylic acids, method for their production and use thereof as medicaments |
| 02/18/2009 | EP2024342A2 Substituted 2-amino-fused heterocyclic compounds |
| 02/18/2009 | EP2024340A1 4,5-diphenyl-pyrimidinyl-amino substituted carboxylic acids, method for the production and use thereof as medicaments |
| 02/18/2009 | EP2024339A1 4,5-diphenyl-pyrimidinyl-oxy or -mercapto substituted carboxylic acids, method for the production and use thereof as medicaments |
| 02/18/2009 | EP2024338A1 4,5-diphenyl-pyrimidinyl substituted carboxylic acids, method for the production and use thereof as medicaments |
| 02/18/2009 | EP2024336A1 Novel pharmaceutical compositions |
| 02/18/2009 | EP2024335A1 Novel imidazole derivatives, preparation and user thereof as medicine |
| 02/18/2009 | EP2024333A2 Amino-ethyl-amino-aryl (aeaa) compounds and their use |
| 02/18/2009 | EP2024332A1 Novel heterocyclic compounds |
| 02/18/2009 | EP2024329A2 (2r)-2-[(4-sulfonyl)aminophenyl]propanamides and pharmaceutical compositions containing them |
| 02/18/2009 | EP2024326A2 Methods for preparing glutamic acid derivatives and intermediates thereof |
| 02/18/2009 | EP2024323A1 Salts of trimebutine and n-desmethyl trimebutine |
| 02/18/2009 | EP2024272A2 Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
| 02/18/2009 | EP2023958A1 Pharmaceutical product for intraoral delivery of nicotine comprising trometamol as buffering agent |
| 02/18/2009 | EP2023956A2 Pharmaceutical combinations comprising a mtor inhibitor and a raf kinase inhibitor |
| 02/18/2009 | EP2023949A2 Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics |
| 02/18/2009 | EP2023942A1 Mixtures of tannins, their production and use in medicaments or as disinfectants |
| 02/18/2009 | EP2023941A2 Protein crosslinkers, crosslinking methods and applications thereof |
| 02/18/2009 | EP2023939A2 Compounds and methods for modulating expression of pcsk9 |
| 02/18/2009 | EP2023938A2 Modulation of chrebp expression |
| 02/18/2009 | EP2023937A2 Rnai modulation of aha and therapeutic uses thereof |
| 02/18/2009 | EP2023936A2 Compositions and their uses directed to ptpr alpha |
| 02/18/2009 | EP2023935A1 Drug administration methods |
| 02/18/2009 | EP2023934A2 3,4-dihydro-2h-benzo[1,4]oxazine and thiazine derivatives as cetp inhibitors |
| 02/18/2009 | EP2023933A2 Acetylenic heteroaryl compounds |
| 02/18/2009 | EP2023932A1 Methods for preventing or treating acute and chronic pain |
| 02/18/2009 | EP2023931A2 Anticancer treatments with a combination of docetaxel and ecteinascidin |
| 02/18/2009 | EP2023930A1 Ionizable inhibitors of fatty acid amide hydrolase |
| 02/18/2009 | EP2023928A1 Coated pharmaceutical product for intraoral delivery of nicotine comprising trometamol as buffering agent |
| 02/18/2009 | EP2023927A2 Deoxynojirimycin and d-arabinitol analogs and methods of using |
| 02/18/2009 | EP2023926A1 Pyridonecarboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders |
| 02/18/2009 | EP2023925A2 Cdki pathway inhibitors as selective inhibitors of tumor cell growth |
| 02/18/2009 | EP2023924A2 Aryl-fused spirocyclic compounds |
| 02/18/2009 | EP2023923A2 Use of ixabepilone in combination with cyp3a4 inhibitors for pharmaceuticals |
| 02/18/2009 | EP2023922A2 Triazole derivatives ii |
| 02/18/2009 | EP2023921A1 Inhibitor of adenylyl cyclase for treating a disorder of the circadian rhythm |
| 02/18/2009 | EP2023920A2 Cannabinoid receptor antagonists/inverse agonists |
| 02/18/2009 | EP2023919A2 Compounds and amyloid probes thereof for therapeutic and imaging uses |
| 02/18/2009 | EP2023918A2 Method for the treatment and prevention of ocular disorders |
| 02/18/2009 | EP2023916A2 Acidic composition |
| 02/18/2009 | EP2023915A2 Borrelidin derivatives as antiproliferative agents and angiogenesis inhibitors |
| 02/18/2009 | EP2023913A2 Methods for treating blood disorders |
| 02/18/2009 | EP2023912A2 Methods and compositions using immunomodulatory compounds in combination therapy |
| 02/18/2009 | EP2023911A2 Compounds a-r-x for the manufacture of pharmaceutical preparations |
| 02/18/2009 | EP2023910A1 Ah receptor antagonists |
| 02/18/2009 | EP2023909A2 Muscarinic agonists to treat impulse control disorders |
| 02/18/2009 | EP2023907A1 Transdermal delivery system comprising sufentanil and its analogues |
| 02/18/2009 | EP2023904A2 Sustained release coated tablet with precisely regulated release profile |
| 02/18/2009 | EP2023901A1 Pharmaceutical composition comprising tetrahydrolipstatin |
| 02/18/2009 | EP2023894A2 Fixed combination dosage forms for the treatment of migraine |
| 02/18/2009 | EP2023769A1 Eyelash applicator and method |
| 02/18/2009 | EP2023747A2 3,5-dihydroxy-2,4-cyclohexadienones and their derivatives, dietary compositions and fortified food containing them and their uses |
| 02/18/2009 | EP2023736A2 Isothiazolinone biocides enhanced by zinc ions |
| 02/18/2009 | EP2023732A2 Oxime derivatives as inhibitors of macrophage migration inhibitory factor |
| 02/18/2009 | EP2023729A2 Organic compounds |
| 02/18/2009 | EP2023728A2 Oxazolyl piperidine modulators of fatty acid amide hydrolase |
| 02/18/2009 | EP2023727A2 Prostaglandin transporter inhibitors |
| 02/18/2009 | EP2023722A2 Toll-like receptor (tlr) stimulation for ocular angiogenesis and macular degeneration |
| 02/18/2009 | EP2023721A2 Preparation and utility of substituted erythromycin analogs |
| 02/18/2009 | EP2023720A2 Tetracyclic imidazole analogs |
| 02/18/2009 | EP1996210A4 Oral hygiene products and method of using the same |
| 02/18/2009 | EP1928833B1 Novel quinoline compounds capable of binding at the cb2 receptor |
| 02/18/2009 | EP1902054B1 Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof and the therapeutic application of the same |
| 02/18/2009 | EP1899333B1 Pyrazolopyridine derivatives as inhibitors of beta-adrenergic receptor kinase 1 |
| 02/18/2009 | EP1861368B1 Process for the preparation of 2-azabicycloý3.3.0¨octane-3-carboxylic acid derivatives |
| 02/18/2009 | EP1831172B1 Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors |
| 02/18/2009 | EP1819238B1 Use of diacetyl trimer as an aromatic and flavouring substance |
| 02/18/2009 | EP1809267B1 Pharmaceutical compositions based on nk2 antagonists for pediatric use |
| 02/18/2009 | EP1773740B1 Neurologically-active compounds |
| 02/18/2009 | EP1758907B1 Diphenylimidazopyrimidine and -imidazole amines as inhibitors of b-secretase |
| 02/18/2009 | EP1748994B1 Nitrooxyderivatives of antihypertensive drugs |
| 02/18/2009 | EP1747201B8 2h or 3h-benzo[e]indazol-1-yle carbamate derivatives, the preparation and therapeutic use thereof |
| 02/18/2009 | EP1732903B1 Triazolone derivatives as mmp inhibitors for the treatment of asthma and copd |
| 02/18/2009 | EP1727801B1 Piperazines useful for treating pain |
| 02/18/2009 | EP1708705B1 Use of piperidine derivatives for promoting angiogenesis |
| 02/18/2009 | EP1699465B1 The use of hydrocortisone to treat depression |
| 02/18/2009 | EP1675852B1 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones |
| 02/18/2009 | EP1664052B1 Fused heterocycles as inhibitors of glutamate racemase (muri) |
| 02/18/2009 | EP1663243B1 Pharmaceutical formulation comprising a pyrimidine-a-one derivative coated with an enteric polymer |
| 02/18/2009 | EP1658255B1 Proteasome inhibitors and methods of using the same |
| 02/18/2009 | EP1658068B1 Novel cycloalkyl[b] condensed indoles |
| 02/18/2009 | EP1641775B1 2-pyridine alkyne derivatives useful for treating pain |
| 02/18/2009 | EP1638582B1 Use of hyaluronic acid for preparing compositions for treating recurrent oral cavity aphthas |
| 02/18/2009 | EP1636279B1 Poly and copoly (n -vinylamide)s and their use in capillary electrophoresis |
| 02/18/2009 | EP1614684B1 Diamine derivative, production process, and antioxidizing drug |
| 02/18/2009 | EP1603886B1 4-substituted-5-cyano-1h-pyrimidin-6-(thi)ones as gsk-3 inhibitors |
| 02/18/2009 | EP1603510A4 Methods of improving skin quality |
| 02/18/2009 | EP1569914B1 Pyrimidine-sulfamides and their use as endothelian receptor antagonist |